These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15495258)

  • 1. Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia.
    Vannorsdall EJ; Collins JA; Chen QC; Sarai G; Baer MR
    Curr Oncol; 2013 Aug; 20(4):e349-53. PubMed ID: 23904774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive systemic mastocytosis of the liver with cholangitis.
    Waldburger N; Rupp C; Klinke S; Wieczorek K; Gotthardt D; Kirchner T; Schirmacher P; Straub BK
    Hepat Oncol; 2015 Oct; 2(4):343-347. PubMed ID: 30191016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17
    Alvarez-Twose I; Matito A; Morgado JM; Sánchez-Muñoz L; Jara-Acevedo M; García-Montero A; Mayado A; Caldas C; Teodósio C; Muñoz-González JI; Mollejo M; Escribano L; Orfao A
    Oncotarget; 2017 Sep; 8(40):68950-68963. PubMed ID: 28978170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment options for mast cell activation disease.
    Molderings GJ; Haenisch B; Brettner S; Homann J; Menzen M; Dumoulin FL; Panse J; Butterfield J; Afrin LB
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):671-94. PubMed ID: 27132234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
    Quintás-Cardama A; Sever M; Cortes J; Kantarjian H; Verstovsek S
    Leuk Lymphoma; 2013 Sep; 54(9):1959-64. PubMed ID: 23278641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report.
    Ozdemir D; Dagdelen S; Erbas T; Agbaht K; Serefhanoglu S; Aksu S; Ersoy-Evans S
    Case Rep Med; 2010; 2010():782595. PubMed ID: 21209730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced mast cell disease: an Italian Hematological Multicenter experience.
    Pagano L; Valentini CG; Caira M; Rondoni M; Van Lint MT; Candoni A; Allione B; Cattaneo C; Marbello L; Caramatti C; Pogliani EM; Iannitto E; Giona F; Ferrara F; Invernizzi R; Fanci R; Lunghi M; Fianchi L; Sanpaolo G; Stefani PM; Pulsoni A; Martinelli G; Leone G; Musto P
    Int J Hematol; 2008 Dec; 88(5):483-488. PubMed ID: 19034614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy.
    Williams P; Sewell WA; Bunn C; Pumphrey R; Read G; Jolles S
    Clin Exp Immunol; 2008 Jul; 153(1):10-8. PubMed ID: 18577028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
    Corless CL; Harrell P; Lacouture M; Bainbridge T; Le C; Gatter K; White C; Granter S; Heinrich MC
    J Mol Diagn; 2006 Nov; 8(5):604-12. PubMed ID: 17065430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mastocytosis: the great masquerader.
    Kong JS; Teuber S; Hallett R; Gershwin ME
    Clin Rev Allergy Immunol; 2006 Feb; 30(1):53-60. PubMed ID: 16461996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.
    Simon J; Lortholary O; Caillat-Vigneron N; Raphaël M; Martin A; Brière J; Barète S; Hermine O; Casassus P;
    Pathol Biol (Paris); 2004 Jun; 52(5):294-9. PubMed ID: 15217717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic mastocytosis: current concepts and treatment advances.
    Tefferi A; Pardanani A
    Curr Hematol Rep; 2004 May; 3(3):197-202. PubMed ID: 15087068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
    Hennessy B; Giles F; Cortes J; O'brien S; Ferrajoli A; Ossa G; Garcia-Manero G; Faderl S; Kantarjian H; Verstovsek S
    Am J Hematol; 2004 Nov; 77(3):209-14. PubMed ID: 15495258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.